Kidney Donation Compatibility: Understanding Donor-Recipient Matching
Determining Compatibility for Kidney Transplantation
Kidney transplantation requires careful matching between donor and recipient to minimize rejection and maximize graft survival. Compatibility is assessed through multiple, complementary evaluations:
1. ABO Blood Group Compatibility
- Donor and recipient must have compatible ABO blood types (identical or compatible, e.g., O to any, A to A/AB, B to B/AB, AB to AB).
- ABO-incompatible transplants are possible with desensitization protocols (plasmapheresis, IVIG, rituximab) but carry higher risk.
- Rh factor does not affect kidney transplant compatibility.
2. HLA Tissue Typing (Human Leukocyte Antigen Matching)
- HLA-A, -B, -DR loci are typed for both parties.
- Better matching (fewer mismatches) correlates with lower rejection rates and longer graft survival, especially for living donor transplants.
- Modern immunosuppression has reduced the absolute requirement for close HLA matching.
3. Crossmatch Testing
- Complement-dependent cytotoxicity (CDC) crossmatch and flow cytometry crossmatch detect preformed anti-donor antibodies in the recipient.
- A negative crossmatch (no donor-specific antibodies) is required for proceeding without desensitization.
- A positive crossmatch indicates high risk of hyperacute or accelerated rejection.
4. Donor Evaluation
- Comprehensive medical, surgical, and psychosocial assessment.
- Exclusion criteria: uncontrolled hypertension, diabetes, significant proteinuria, GFR <80 mL/min, active malignancy, infections, psychiatric instability.
- Imaging (CT angiography) to evaluate renal anatomy and vascular suitability.
5. Living vs. Deceased Donor
- Living donor: Preferred—better organ quality, shorter cold ischemia time, planned surgery, superior long-term outcomes.
- Deceased donor: Allocated via waiting list (e.g., UNOS/KDPI in US); includes donation after brain death (DBD) and circulatory death (DCD).
6. Ethical and Legal Framework
- Informed, voluntary consent; no coercion or financial incentive.
- Independent donor advocate team.
- Compliance with national regulations (e.g., NOTA in US, Human Tissue Act in UK).
7. Recipient Suitability
- Absence of active infection, uncontrolled malignancy, severe irreversible cardiac/pulmonary/hepatic disease.
- Adequate social support and adherence capacity for lifelong immunosuppression.
8. Long-Term Follow-Up
Both donor and recipient require lifelong monitoring: graft function (creatinine, eGFR), immunosuppression levels, metabolic complications, cancer screening, and quality of life. Donor follow-up includes annual renal function and blood pressure checks.
Kidney Disease - Related Articles
- Understanding End-Stage Renal Failure (ESRF): Causes & Facts
- Drugs for Kidney Health: Improving Kidney Function & Disease Management
- Dialysis Frequency: Is Weekly Treatment Appropriate?
- Choosing a Dialysis Center: A Comprehensive Rating Guide
- End-Stage Renal Disease (ESRD) Diet: Nutrition & Management
- Low Hemoglobin: Causes, Symptoms & Iron Deficiency - OhioHealth
- Post-Kidney Donation Recovery: What to Expect After Hospital Discharge
